90 patents
Page 2 of 5
Utility
Use of CYP26-RESISTANT Rar Alpha Selective Agonists In the Treatment of Cancer
16 Jun 22
Disclosed herein are methods for treating a cancer comprising administering to a subject in need thereof an effective dose of a CYP26-resistant retinoic acid receptor (RAR) alpha (RARα) selective agonist, whereby as a result of the treatment the tumor burden is reduced in the subject and cancer stem cells resident in the bone marrow are substantially reduced.
Gabriel Ghiaur, Richard J. Jones, Salvador Alonso, Roshantha A. Chandraratna
Filed: 3 Mar 22
Utility
Treatment of Autoimmune Diseases with Combinations of RXR Agonists and Thyroid Hormones
12 May 22
The present specification provides methods of treating autoimmune diseases with a combination of a RXR agonist and a thyroid hormone.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 26 Jan 22
Utility
Autoimmune Disorder Treatment Using RXR Agonists
21 Apr 22
The present specification provides RXR agonist compounds, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RXR agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.
Roshantha A. Chandraratna, Ethan Dmitrovsky, Elizabeth Nowak, Randolph Noelle
Filed: 22 Dec 21
Utility
Autoimmune disorder treatment using RXR agonists
15 Feb 22
The present specification provides RXR agonist compounds, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RXR agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.
Roshantha A. Chandraratna, Ethan Dmitrovsky, Elizabeth Nowak, Randolph Noelle
Filed: 18 Dec 20
Utility
Use of an RXR agonist in treating HER2+ cancers
18 Jan 22
The present specification provides combinations of active agents for the improved treatment of Her2+ cancers and associated methods of treatments.
Martin E. Sanders, Powel H. Brown
Filed: 18 Dec 20
Utility
Autoimmune disorder treatment using RXR agonists
9 Nov 21
The present specification provides RXR agonist compounds, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RXR agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.
Roshantha A. Chandraratna, Ethan Dmitrovsky, Elizabeth Nowak, Randolph Noelle
Filed: 18 Dec 20
Utility
Treatment of Nervous System Disorders Using Combinations of RXR Agonists and Thyroid Hormones
14 Oct 21
Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 18 Jun 21
Utility
Receptor Subtype and Function Selective Retinoid and Rexinoid Compounds In Combination with Immune Modulators for Cancer Immunotherapy
9 Sep 21
Disclosed herein are methods for treating cancer comprising administering at least one immune checkpoint inhibitor and at least one Retinoic Acid Receptor or Retinoid X Receptor active agent.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 26 Mar 21
Utility
Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones
20 Jul 21
Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 2 Apr 19
Utility
Treatment of Cancer with Specific RXR Agonists
8 Jul 21
A method of treating cancer is disclosed comprising administering to a patient in need of such treatment a RXR agonist at a level below the RAR activating threshold and at or above the RXR effective dose.
Roshantha A. Chandraratna
Filed: 22 Mar 21
Utility
Treatment of Autoimmune Diseases with Combinations of RXR Agonists and Thyroid Hormones
3 Jun 21
The present specification provides methods of treating autoimmune diseases with a combination of a RXR agonist and a thyroid hormone.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 15 Jan 21
Utility
Use of CYP26-RESISTANT Rar Alpha Selective Agonists In the Treatment of Cancer
13 May 21
Disclosed herein are methods for treating a cancer comprising administering to a subject in need thereof an effective dose of a CYP26-resistant retinoic acid receptor (RAR) alpha (RARα) selective agonist, whereby as a result of the treatment the tumor burden is reduced in the subject and cancer stem cells resident in the bone marrow are substantially reduced.
Gabriel Ghiaur, Richard J. Jones, Salvador Alonso, Roshantha A. Chandraratna
Filed: 28 Dec 20
Utility
Use of CYP26-RESISTANT Rar Alpha Selective Agonists In the Treatment of Cancer
13 May 21
Disclosed herein are methods for treating a cancer comprising administering to a subject in need thereof an effective dose of a CYP26-resistant retinoic acid receptor (RAR) alpha (RARα) selective agonist, whereby as a result of the treatment the tumor burden is reduced in the subject and cancer stem cells resident in the bone marrow are substantially reduced.
Gabriel Ghiaur, Richard J. Jones, Salvador Alonso, Roshantha A. Chandraratna
Filed: 29 Dec 20
Utility
Use of an RXR Agonist In Treating HER2+ Cancers
13 May 21
The present specification provides combinations of active agents for the improved treatment of Her2+ cancers and associated methods of treatments.
Martin E. Sanders, Powel H. Brown
Filed: 18 Dec 20
Utility
Compounds and Synthetic Methods for the Preparation of Retinoid X Receptor-specific Retinoids
13 May 21
Provided herein are compounds useful for the preparation of compounds that have retinoid-like biological activity.
Roshantha A. Chandraratna, Vidyasagar Pradeep Vuligonda, Thomas Jacks, Peter Wade, Andrew Thompson
Filed: 13 Jan 21
Utility
Autoimmune Disorder Treatment Using RXR Agonists
6 May 21
The present specification provides RXR agonist compounds, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RXR agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.
Roshantha A. Chandraratna, Ethan Dmitrovsky, Elizabeth Nowak, Randolph Noelle
Filed: 18 Dec 20
Utility
Autoimmune Disorder Treatment Using RXR Agonists
6 May 21
The present specification provides RXR agonist compounds, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RXR agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.
Roshantha A. Chandraratna, Ethan Dmitrovsky, Elizabeth Nowak, Randolph Noelle
Filed: 18 Dec 20
Utility
Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones
27 Apr 21
Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 2 Jul 20
Utility
Immunomodulatory and Differentiating Function Selective Retinoid and Rexinoid Compounds In Combination with Immune Modulators for Cancer Immunotherapy
22 Apr 21
Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor and/or Retinoid X Receptor active agent.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 16 Dec 20
Utility
Receptor Subtype and Function Selective Retinoid and Rexinoid Compounds In Combination with Immune Modulators for Cancer Immunotherapy
22 Apr 21
Disclosed herein are methods for culturing CAR-modified immune cells with at least one Retinoic Acid Receptor and/or Retinoid X Receptor active agent.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 16 Dec 20